The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

High threshold clinical responses (Investigator’s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index ... while IZAR-2 will enroll patients with an inadequate response to tumor ...

The anti-IL-23 monoclonal antibody, called picankibart, was shown to clear or nearly clear all lesions after 16 weeks among 48.2% of the 82 participating Chinese patients that were classified as ...

Investigators aimed to highlight aspects that may predict the time to relapse among patients with psoriasis who discontinued use of biologic therapy.

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

Innovent Biologics (IVBXF) announced the latest clinical results of a multicenter, open-label Phase 2 study of picankibart, a recombinant ...

Because of its numerous roles, it was thought that inhibition of TNF may aid in the treatment of certain dermatologic diseases such as psoriasis, hidradentitis suppurativa, pyoderma gangrenosum ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

A 20-year-old female presented with a history of psoriasis and psoriatic arthritis ... inhibits the pro-inflammatory cytokine TNF-α. It is approved for use in rheumatoid arthritis, juvenile ...

In a systematic review, the incidence of gastrointestinal-related adverse events associated with the use of biologic therapies for psoriasis was 8.7%.